Pemirolast (potassium)

Pemirolast potassium is an orally active antiallergic agent. Pemirolast potassium attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast potassium can be used for bronchial asthma and conjunctivitis research^[1]-[5]. In Vitro:Pemirolast (1 μM-1 mM) potassium inhibits A23187-induced LTC4 and ECP release from the eosinophils in a dose-dependent manner^[1].
Pemirolast (0.1-1 mM) potassium also inhibits PAF-induced and FMLP-induced ECP release from the eosinophils^[1].
Pemirolast potassium prevents the activation of human eosinophils to inhibit granule protein LTQ and ECP release, so that alleviates controlling allergic diseases^[1].
Pemirolast (100 nM-1 mM; 1-15 min) potassium fails to significantly inhibit histamine release from human conjunctival mast cells^[2].
Pemirolast (0.1 μg/mL-0.01 mg/mL) potassium inhibits the activation of signal transduction phospholipases C and AZ in rat peritoneal mast cells, by inhibiting the degranulation reaction of antigen and compound 48/80, suppressing the formation of 1,2-diacylglycerol and phosphatidylic acid^[3]. In Vivo:Pemirolast potassium potently attenuates Paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats^[4].
Pemirolast (0.1-1 mg/kg; i.v.) potassium inhibits taxel-induced pulmonary vascular hyperpermeability, and reverses paclitaxel-induced arterial PaO2 decreasing at a dosage of 1 mg/kg, 30 minutes after paclitaxel (HY-B0015) injection (15 mg/kg; i.v.)^[4].
Pemirolast (10 mg/kg/d; p.o.; 4-5 d) potassium significantly reduces Cisplatin (HY-17394)-induced kaolin intake on days 3 and 4 and inhibits cisplatin-induced substance P release in the cerebrospinal fluid (CSF) in rats^[5].